Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 1) DOI Creative Commons
Ashot Avagimyan, Mohammad Sheibani, А. И. Трофименко

et al.

Innovative medicine of Kuban, Journal Year: 2024, Volume and Issue: 4, P. 126 - 135

Published: Nov. 15, 2024

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have emerged as a revolutionary class of drugs with far-reaching protective effects in multiple organs. The potential SGLT2i is much broader than that the classical concept glucose control and consists an entire conglomerate associated pleiotropic effects. This study aims to provide descriptive review therapeutic SGLT2i. first part literature examined use cardiology nephrology. represents innovative approach improving patients’ quality life course heart failure chronic kidney disease, regardless left ventricular ejection fraction type diabetes.

Language: Английский

Delayed cardiac consequences unveiled by magnetic resonance imaging in a high‐voltage electric shock survivor DOI Creative Commons
Golnaz Houshmand, Majid Sadeghpour, Faezeh Tabesh

et al.

ESC Heart Failure, Journal Year: 2025, Volume and Issue: unknown

Published: March 4, 2025

Language: Английский

Citations

0
Targeted Drug Delivery System for Pulmonary Fibrosis: Design and Development of Biomaterials DOI Creative Commons
Jinsha Liu,

Zifeng Pan,

Aatif Khan

et al.

BIO Integration, Journal Year: 2025, Volume and Issue: 6(1)

Published: Jan. 1, 2025

Pulmonary fibrosis (PF) is a progressive interstitial lung disease characterized by excessive extracellular matrix deposition and tissue scarring, leading to impaired function respiratory failure. Although current treatments, such as pirfenidone nintedanib, slow progression, they fail completely halt or reverse fibrosis. Therefore, innovative therapeutic strategies are needed. Targeted drug delivery systems (TDDSs) emerging promising solutions. Biomaterials play critical roles in these enhancing specificity, availability, efficacy, while minimizing systemic toxicity. The most notable biomaterials include nanotechnology-based systems, including liposomes polymeric nanoparticles, which facilitate penetration release fibrotic tissues. Hydrogels have three-dimensional structures providing controlled sustained at inflammation sites, therefore particularly valuable PF treatment. Furthermore, biological carriers stem cells vesicles biocompatibility anti-inflammatory effects that improve outcomes. Despite the potential of clinical translation hindered several challenges, immune clearance, stability platforms, optimization retention within diseased Interdisciplinary approaches integrating precision medicine with advancements may provide solutions opening new avenues for This review discusses developments targeted PF, emphasizing importance biomaterials, mechanisms barriers involved pulmonary delivery, future perspectives overcoming limitations. ultimate goal patient outcomes revolutionizing approach treatment through advanced technologies.

Language: Английский

Citations

0
Pathobiology of myocardial and cardiomyocyte injury in ischemic heart disease: Perspective from seventy years of cell injury research DOI Creative Commons
L. Maximilian Buja

Experimental and Molecular Pathology, Journal Year: 2024, Volume and Issue: 140, P. 104944 - 104944

Published: Nov. 21, 2024

Language: Английский

Citations

3
Current Concepts in the Epigenetic Regulation of Cardiac Fibrosis DOI Creative Commons
Ali Fatehi Hassanabad, Anna N. Zarzycki, Vaibhav B. Patel

et al.

Cardiovascular Pathology, Journal Year: 2024, Volume and Issue: 73, P. 107673 - 107673

Published: July 10, 2024

Cardiac fibrosis is a significant driver of congestive heart failure, syndrome that continues to affect growing patient population globally. results from constellation complex processes at the transcription, receptor, and signaling axes levels. Various mediators cascades, such as transformation growth factor-beta pathway, have been implicated in pathophysiology cardiac tissue fibrosis. Our understanding these markers pathways has improved recent years more advanced technologies assays developed, allowing for better delineation crosstalk between specific factors. There mounting evidence suggesting epigenetic modulation plays pivotal role progression Transcriptional regulation key pro- anti-fibrotic can accentuate or blunt rate extent level. Exosomes, micro-RNAs, long non-coding RNAs all belong factors impact signature Herein, we comprehensively review latest literature about exosomes, their contents, In doing so, highlight transcriptional with properties. We also assimilate data supporting mediators' potential utility diagnostic prognostic biomarkers. Finally, offer insight into where further work be done fill existing gaps translate pre-clinical findings improve clinical outcomes.

Language: Английский

Citations

2
Protective Potential of Sodium-Glucose Cotransporter 2 Inhibitors in Internal Medicine (Part 1) DOI Creative Commons
Ashot Avagimyan, Mohammad Sheibani, А. И. Трофименко

et al.

Innovative medicine of Kuban, Journal Year: 2024, Volume and Issue: 4, P. 126 - 135

Published: Nov. 15, 2024

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have emerged as a revolutionary class of drugs with far-reaching protective effects in multiple organs. The potential SGLT2i is much broader than that the classical concept glucose control and consists an entire conglomerate associated pleiotropic effects. This study aims to provide descriptive review therapeutic SGLT2i. first part literature examined use cardiology nephrology. represents innovative approach improving patients’ quality life course heart failure chronic kidney disease, regardless left ventricular ejection fraction type diabetes.

Language: Английский

Citations

1